Patents by Inventor David Andrew Coates

David Andrew Coates has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted [(5-pyrrolo[2,1-c][1,4]benzodiazepin-11-yl)piperazin-1-yl]-2,2-dimethylpropanoic acid compounds as dual activity H1 inverse agonists/5-HTantagonists
    Patent number: 8314092
    Abstract: A dual H1/5-HT2A receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: November 20, 2012
    Assignee: Eli Lilly and Company
    Inventors: Anne Marie Camp, Peter Thaddeus Gallagher, Andrew James Ledgard, Adam Jan Sanderson, David Andrew Coates
  • Oxazolo[5-4-b]pyridin-5-yl compounds
    Patent number: 8288548
    Abstract: The present invention provides oxazolo[5,4-b]pyridin-5-yl compounds useful in the treatment of cancer.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: October 16, 2012
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Raymond Gilmour, Jose Alfredo Martin, Eva Maria Martin de la Nava
  • SUBSTITUTED [(5H-PYRROLO[2,1-c][1,4]BENZODIAZEPIN-11-YL)PIPERAZIN-1-YL]-2,2-DIMETHYLPROPANOIC ACID COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS
    Publication number: 20120202797
    Abstract: A dual H1/5-HT2A receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Application
    Filed: January 25, 2012
    Publication date: August 9, 2012
    Applicant: Eli Lilly and Company
    Inventors: Anne Marie CAMP, Peter Thaddeus GALLAGHER, Andrew James LEDGARD, Adam Jan SANDERSON, David Andrew COATES
  • OXAZOLO[5-4-b]PYRIDIN-5-YL COMPOUNDS
    Publication number: 20120142724
    Abstract: The present invention provides oxazolo[5,4-b]pyridin-5-yl compounds useful in the treatment of cancer.
    Type: Application
    Filed: November 17, 2011
    Publication date: June 7, 2012
    Applicant: Eli Lilly and Company
    Inventors: David Andrew Coates, Raymond Gilmour, Jose Alfredo Martin, Eva Maria Martin de la Nava
  • MINERALOCORTICOID RECEPTOR ANTAGONIST AND METHODS OF USE
    Publication number: 20110312954
    Abstract: The present invention provides a compound of the formula: Compound (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising Compound (I) in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart failure, hypertension, diabetic nephropathy, or chronic kidney disease, comprising administering Compound (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 4, 2010
    Publication date: December 22, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: David Andrew Coates, Konstantinos Gavardinas, Prabhakar Kondaji Jadhav
  • Crystalline Forms Of [R-(R*,R*)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methyl- Ethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic Acid Calcium Salt (2:1)
    Publication number: 20080287521
    Abstract: Novel crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.
    Type: Application
    Filed: July 14, 2008
    Publication date: November 20, 2008
    Inventors: Stephen Robert Byrn, David Andrew Coates, Karen Sue Gushurst, Joseph Francis Krzyzaniak, Zheng Jane Li, Henry Grant Morrison, II, Aeri Park, Petinka Ivanova Vlahova
  • Crystalline forms of [R-(R*, R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)
    Publication number: 20080214651
    Abstract: Novel crystalline forms of [R—(R*,R*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.
    Type: Application
    Filed: October 25, 2007
    Publication date: September 4, 2008
    Inventors: Stephen Robert Byrn, David Andrew Coates, Karen Sue Gushurst, Joseph Francis Krzyzaniak, Zheng Jane Li, Henry Grant Morrison, Aeri Park, Petinka Ivanova Vlahova
  • Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)
    Patent number: 7144915
    Abstract: Novel crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.
    Type: Grant
    Filed: June 6, 2003
    Date of Patent: December 5, 2006
    Assignee: Warner-Lambert Company, LLC
    Inventors: Stephen Robert Byrn, David Andrew Coates, Karen Sue Gushurst, Joseph Francis Krzyzaniak, Zheng Jane Li, Henry Grant Morrison, II, Aeri Park, Petinka Ivanova Vlahova
  • Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)
    Publication number: 20040054193
    Abstract: Novel crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-&bgr;,&dgr;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.
    Type: Application
    Filed: June 6, 2003
    Publication date: March 18, 2004
    Inventors: Stephen Robert Byrn, David Andrew Coates, Karen Sue Gushurst, Joseph Francis Krzyzaniak, Zheng Jane Li, Henry Grant Morrison, Aeri Park, Petinka Ivanova Vlahova
  • Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-&bgr;,&dgr;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)
    Patent number: 6605729
    Abstract: Novel crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-&bgr;,&dgr;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: August 12, 2003
    Assignee: Warner-Lambert Company
    Inventors: Stephen Robert Byrn, David Andrew Coates, Karen Sue Gushurst, Joseph Francis Krzyzaniak, Zheng Jane Li, Henry Grant Morrison, II, Aeri Park, Petinka Ivanova Vlahova